Impact of the Italian Society of Anatomic Pathology and Diagnostic Cytology Classification of Thyroid Nodules in the Treatment of Indeterminate Follicular Lesions: Five-Year Results at a Single Center.
Journal
International journal of endocrinology
ISSN: 1687-8337
Titre abrégé: Int J Endocrinol
Pays: Egypt
ID NLM: 101516376
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
11
2019
revised:
03
03
2020
accepted:
09
03
2020
entrez:
1
5
2020
pubmed:
1
5
2020
medline:
1
5
2020
Statut:
epublish
Résumé
Aim of the study was to assess the impact of the Italian Society of Anatomic Pathology and Diagnostic Cytology (SIAPEC) classification of 2014, on the treatment of indeterminate thyroid lesions (TIR3). We retrospectively analyzed patients undergoing thyroid surgery for TIR3 lesions between 2013 and 2018, at the General Surgery Department of Trieste University Hospital. According to the SIAPEC classification, patients were divided into TIR3A and TIR3B groups. All patients treated before 2014 underwent surgical treatment, and surgical specimens were retrospectively classified after revision of fine-needle aspiration cytology. Starting 2014, TIR3A patients were treated only when symptomatic (i.e., coexistent bilateral thyroid goiter or growing TIR3A nodules), whereas TIR3B patients always received surgical treatment. Hemithyroidectomy (HT) was the procedure of choice. Total thyroidectomy (TT) was performed in case of concurrent bilateral goiter, autoimmune thyroid disease, and/or presence of BRAF and/or RAS mutation. Lastly, we analyzed the malignancy rate in the two groups. 29 TIR3A and 90 TIR3B patients were included in the study. HT was performed in 10 TIR3A patients and 37 TIR3B patients, respectively, with need for reoperation in 4 TIR3B (10.8%) patients due to histological findings of follicular thyroid carcinoma >1 cm. The malignancy rates were 17.2% in TIR3A and 31.1% in TIR3B, ( The new SIAPEC classification in association with biomolecular markers has improved diagnostic accuracy, patient selection, and clinical management of TIR3 lesions.
Identifiants
pubmed: 32351561
doi: 10.1155/2020/7325260
pmc: PMC7178537
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7325260Informations de copyright
Copyright © 2020 M. Pastoricchio et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
Endocrine. 2017 Feb;55(2):530-538
pubmed: 27075721
Diagn Mol Pathol. 2008 Jun;17(2):118-25
pubmed: 18382358
Thyroid. 1996 Oct;6(5):409-16
pubmed: 8936664
Thyroid. 2011 Mar;21(3):243-51
pubmed: 21190442
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
J Clin Endocrinol Metab. 2006 Sep;91(9):3411-7
pubmed: 16835280
Cancer. 2013 Apr 15;119(8):1495-502
pubmed: 23280049
Diagn Cytopathol. 2002 Jan;26(1):41-4
pubmed: 11782086
J Clin Endocrinol Metab. 2012 Jul;97(7):2354-61
pubmed: 22535974
Int J Environ Res Public Health. 2016 Apr 22;13(4):442
pubmed: 27110805
Endocr Pract. 2012 Sep-Oct;18(5):796-802
pubmed: 22982803
Thyroid. 2017 Jan;27(1):39-48
pubmed: 27750019
Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):901-11
pubmed: 19041821
Otolaryngol Head Neck Surg. 2017 Apr;156(4):611-615
pubmed: 28118554
J Natl Cancer Inst. 2003 Apr 16;95(8):625-7
pubmed: 12697856
N Engl J Med. 2004 Oct 21;351(17):1764-71
pubmed: 15496625
J Clin Endocrinol Metab. 2011 Mar;96(3):658-64
pubmed: 21239517
Cytopathology. 2017 Dec;28(6):503-508
pubmed: 28913847
Eur Thyroid J. 2015 Dec;4(4):246-51
pubmed: 26835428
Cancer Med. 2019 Sep;8(12):5577-5589
pubmed: 31397092
Pathologica. 2010 Oct;102(5):405-8
pubmed: 21361121
Thyroid. 2011 Jul;21(7):717-23
pubmed: 21568726
Cancer Cytopathol. 2015 Dec;123(12):713-22
pubmed: 26355876
Int J Surg. 2017 May;41 Suppl 1:S34-S39
pubmed: 28506411
Endokrynol Pol. 2016;67(1):41-7
pubmed: 26884114
Otolaryngol Head Neck Surg. 2017 Mar;156(3):472-479
pubmed: 28116986
Arch Intern Med. 1994 Aug 22;154(16):1838-40
pubmed: 8053752
Thyroid. 2013 Nov;23(11):1408-15
pubmed: 23509895
Cancer Cytopathol. 2016 Jan;124(1):14-27
pubmed: 26348024
Radiology. 2011 Sep;260(3):892-9
pubmed: 21771959
Cancer. 2007 Dec 25;111(6):508-16
pubmed: 17999413
Clin Cancer Res. 2004 Apr 15;10(8):2761-5
pubmed: 15102681
World J Surg. 2010 Nov;34(11):2589-94
pubmed: 20703476
Thyroid. 2009 Nov;19(11):1167-214
pubmed: 19860577
Lancet. 2003 Feb 8;361(9356):501-11
pubmed: 12583960
Oncologist. 2010;15(12):1285-93
pubmed: 21147872
Ann Intern Med. 1997 Feb 1;126(3):226-31
pubmed: 9027275
Endocr Pract. 2016 May;22(5):622-39
pubmed: 27167915
Am J Clin Pathol. 2011 Jun;135(6):852-9
pubmed: 21571958
Clin Endocrinol (Oxf). 2014 Jul;81 Suppl 1:1-122
pubmed: 24989897
Am J Clin Pathol. 2009 Nov;132(5):658-65
pubmed: 19846805
J Clin Endocrinol Metab. 2003 May;88(5):2318-26
pubmed: 12727991
Ann Intern Med. 1993 Feb 15;118(4):282-9
pubmed: 8420446
Eur J Clin Invest. 2009 Aug;39(8):699-706
pubmed: 19601965
Endocrine. 2019 Mar;63(3):430-438
pubmed: 30519908
Acta Cytol. 2012;56(4):333-9
pubmed: 22846422
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Endocrinol Invest. 2019 Jan;42(1):1-6
pubmed: 29546655
J Endocrinol Invest. 2010 May;33(5):287-91
pubmed: 20479572
Pathol Res Pract. 2000;196(1):1-7
pubmed: 10674266
J Endocrinol Invest. 2018 May;41(5):531-538
pubmed: 28948534
Int J Endocrinol. 2017;2017:9692304
pubmed: 28348589
J Clin Endocrinol Metab. 2011 Nov;96(11):3390-7
pubmed: 21880806
Thyroid. 2009 Aug;19(8):837-42
pubmed: 19534623
Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):240-8
pubmed: 17315032
Thyroid. 2003 Apr;13(4):381-7
pubmed: 12804106
Surgery. 2015 Feb;157(2):354-61
pubmed: 25616949